Tirzepatide Interactions

Tirzepatide slows how quickly the stomach empties, and that slowing is strongest right after the first dose and after each dose increase. A birth control pill relies on being absorbed promptly and completely; when the stomach holds onto it, peak hormone levels fall by more than half. The FDA label instructs patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after every dose increase. Contraceptives that are not swallowed are not affected.

Thiamine (vitamin B1) is the nutrient the brain exhausts fastest — reserves last only weeks. Tirzepatide commonly reduces appetite and can cause prolonged nausea or vomiting, and where intake collapses for long enough, thiamine can run out. Running out causes Wernicke encephalopathy: confusion, unsteady walking and abnormal eye movements. It is reversible if treated within hours and can be permanent if missed. Eighteen cases have been published, fifteen of them following GLP-1 use, and in most the vomiting or poor intake came first.

These medicines make the stomach empty much more slowly. Indigestible plant fibre that sits in a slow stomach long enough can mat together into a solid ball called a bezoar. In one endoscopy series, four of twenty-three patients taking a GLP-1 medicine had a gastric bezoar of four centimetres or more, and none of the seventy-seven patients not taking one did. A concentrated fibre supplement adds exactly the material these are formed from. Bulk fibre also swells with water and can lodge in the food pipe if taken with too little fluid.

Tirzepatide lowers blood sugar, but on its own it rarely causes a dangerous low because it only prompts insulin release when blood sugar is already raised. insulin does not work that way — it drives insulin regardless of the current level. Combined, the glucose-lowering adds up and blood sugar can fall too far, and eating less on Tirzepatide removes the buffer that would normally protect against it. Every FDA label in this class carries the same instruction.

Tirzepatide lowers blood sugar, but on its own it rarely causes a dangerous low because it only prompts insulin release when blood sugar is already raised. a sulfonylurea such as glipizide does not work that way — it drives insulin regardless of the current level. Combined, the glucose-lowering adds up and blood sugar can fall too far, and eating less on Tirzepatide removes the buffer that would normally protect against it. Every FDA label in this class carries the same instruction.